Oppenheimer initiated coverage on Immunovant Sciences with a new price target
$IMVT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Oppenheimer initiated coverage of Immunovant Sciences with a rating of Outperform and set a new price target of $50.00